To include your compound in the COVID-19 Resource Center, submit it here.

Immune modulation therapy: VAS will begin in 4Q02 a North American Phase III trial in about 1,500 patients. Previously reported data from a North American Phase

Vasogen Inc. (TSE:VAS; VSV), Toronto, Ontario
Product: Immune modulation therapy (formerly

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE